search
Back to results

Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis (Fibro-ALS)

Primary Purpose

Sporadic Amyotrophic Lateral Sclerosis

Status
Unknown status
Phase
Early Phase 1
Locations
Study Type
Interventional
Intervention
Skin Biopsy
Sponsored by
University Hospital, Angers
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Sporadic Amyotrophic Lateral Sclerosis focused on measuring Bioenergetics, Protein Metabolism, Sporadic Amyotrophic Lateral Sclerosis

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria :

  • a free signed an written consent
  • aged between 18 and 80 years old
  • ALS defined by El Escorial Criteria
  • normal neurological examination

Exclusion criteria:

  • comorbidity or treatment susceptible to impact on metabolism
  • differential diagnosis suspected, early and late forms (<6 month > 3 years)
  • ALS not defined by El Escorial Criteria
  • withdrawal of consent to participate

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Other

    Other

    Arm Label

    Patients

    Controls

    Arm Description

    ALS defined by El Escorial Criteria.

    Asymptomatic subjects with normal examination.

    Outcomes

    Primary Outcome Measures

    Kinetics of fibroblast growth
    The growth rates of the fibroblast lines

    Secondary Outcome Measures

    Mitochondrial metabolism
    the breath parameters of fibroblast will be precisely studied by oxygraphy, a method consisting in measuring the oxygen consumption rates of fibroblasts in different metabolic phases
    Protéic metabolism
    The presence of intracytoplasmic inclusion of target protein will be sought.
    stress in senescence answer
    the answer due to the stress of cell lines in hypoxia and nutritionnal lack will be studied.

    Full Information

    First Posted
    November 4, 2016
    Last Updated
    November 22, 2016
    Sponsor
    University Hospital, Angers
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02969759
    Brief Title
    Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
    Acronym
    Fibro-ALS
    Official Title
    Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2016
    Overall Recruitment Status
    Unknown status
    Study Start Date
    November 2016 (undefined)
    Primary Completion Date
    November 2017 (Anticipated)
    Study Completion Date
    November 2019 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    University Hospital, Angers

    4. Oversight

    5. Study Description

    Brief Summary
    INTRODUCTION: Amyotrophic Lateral Sclerosis (ALS) is a degenerative disease of the motor neurones of the brain and the spinal cord. The pathophysiological mechanisms of the disease remain unknown. The average age of onset of ALS is about 60 years old, and the mean survival of patients is about 2 years. The disease is responsible for a progressive paralysis leading to death from respiratory failure. The only treatment available is the Riluzole, with a very modest efficiency on the progression of the disease. ALS is the third neurodegenerative disease, affecting 6000 persons in France, 150 000 in the world. Among the protagonists involved in the occurrence of the disease, mitochondrial perturbations and protein accumulations seem to be central elements. OBJECTIVES: To precise the implication of energy and protein metabolism in the sporadic forms of ALS, to identify potential biomarkers of the disease and to test new therapies. METHODS: The investigators will study cell growth, bioenergetics, mitochondrial dynamics, free-radicals production, presence of cytoplasmic inclusions, cytoskeleton structure and stress response in primary skin fibroblasts obtained from sporadic ALS patients. The study will be conducted over a period of three years in 3 centres specialized respectively in motor neuron diseases, mitochondrial metabolism and neuronal cytoskeleton. PROSPECTS: If the investigators achieve to identify differences between ALS fibroblasts and controls, the results will be key elements to reinforce the hypothesis of a systemic disease with an important metabolic participation, to better define ALS pathophysiological mechanisms, to find potential biomarkers and to test new therapies.
    Detailed Description
    The investigators will study fibroblasts derived from sporadic ALS patients. Clinical parameters will be collected such as sex, age, age of onset, clinical presentation, electrophysiological an respiratory parameters, treatments. Patients and controls derived fibroblasts will be amplified and cultivated from skin biopsies. Primary fibroblast cell cultures will be derived from skin biopsies obtained from control subjects and from the patients after obtaining written consent. Amplifications will be performed, from passage 1 to 6, allowing the time for cell cryopreservation of 10 samples per cell line. All experiments will be conducted on cells with similar passage numbers, ranging from 6 to 25, to avoid artefacts due to senescence. Cell growth of each line will be monitored with the IncuCyte ZOOM® system (Essen Biosciences), a microscope gantry that resides in a cell incubator, and a networked external controller hard drive that gathers and processes image data. Cell growth will be automatically calculated at each time point using the relative cell density (ratio of the occupied area to the total area of the acquired regions). The respiratory parameters of the fibroblasts will be monitored precisely with an high resolution oxygraph (OROBOROS). Enzymatic activity of each complex of the mitochondrial respiratory chain will be measured by spectrometry, and the mitochondrial membrane potential will be studied with fluorescence microscopy (TMRM probe). The investigators will also study mitochondrial dynamics and the architecture of mitochondrial network with fluorescence microscopy and super-resolution microscopy (SRM, Roper). The production of free radicals will be estimated with probes sensitive to oxidative stress. Finally, a metabolomic study (mass spectrometry QTRAP LC/MS/MS 5500 ABSciex) will be performed to characterise precisely the metabolites in the cells and to assess their metabolic profile. The investigators will search for protein inclusions (intermediate filaments, TDP43, FUS, ubiquitin) with immuno-fluorescence technics. Western Blots will be performed to study the protein metabolism. The architecture of the cytoskeleton will be analysed in SRM and fluorescence microscopy, and the investigators will try to transfect fibroblasts in order to express Neurofilaments and study the consequences on the cytoskeleton and protein metabolism. The investigators will study the response of the cells to the stress (hypoxia SCI-tive Dual, starvation), and to senescence (high passage numbers).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Sporadic Amyotrophic Lateral Sclerosis
    Keywords
    Bioenergetics, Protein Metabolism, Sporadic Amyotrophic Lateral Sclerosis

    7. Study Design

    Primary Purpose
    Basic Science
    Study Phase
    Early Phase 1
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    30 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Patients
    Arm Type
    Other
    Arm Description
    ALS defined by El Escorial Criteria.
    Arm Title
    Controls
    Arm Type
    Other
    Arm Description
    Asymptomatic subjects with normal examination.
    Intervention Type
    Other
    Intervention Name(s)
    Skin Biopsy
    Primary Outcome Measure Information:
    Title
    Kinetics of fibroblast growth
    Description
    The growth rates of the fibroblast lines
    Time Frame
    24 hours
    Secondary Outcome Measure Information:
    Title
    Mitochondrial metabolism
    Description
    the breath parameters of fibroblast will be precisely studied by oxygraphy, a method consisting in measuring the oxygen consumption rates of fibroblasts in different metabolic phases
    Time Frame
    24 hours
    Title
    Protéic metabolism
    Description
    The presence of intracytoplasmic inclusion of target protein will be sought.
    Time Frame
    24 hours
    Title
    stress in senescence answer
    Description
    the answer due to the stress of cell lines in hypoxia and nutritionnal lack will be studied.
    Time Frame
    24 hours

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion criteria : a free signed an written consent aged between 18 and 80 years old ALS defined by El Escorial Criteria normal neurological examination Exclusion criteria: comorbidity or treatment susceptible to impact on metabolism differential diagnosis suspected, early and late forms (<6 month > 3 years) ALS not defined by El Escorial Criteria withdrawal of consent to participate

    12. IPD Sharing Statement

    Learn more about this trial

    Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis

    We'll reach out to this number within 24 hrs